2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalence
2016
Impact of nurse-delivered community-based CD4 services on facilitating pre-ART care in rural South Africa
Kompala T, Moll AP, Mtungwa N, Brooks RP, Friedland GH, Shenoi SV. Impact of nurse-delivered community-based CD4 services on facilitating pre-ART care in rural South Africa. BMC Health Services Research 2016, 16: 374. PMID: 27515233, PMCID: PMC4982129, DOI: 10.1186/s12913-016-1627-8.Peer-Reviewed Original ResearchConceptsPre-ART careAntiretroviral treatmentCD4 testingCBVCT servicesTreatment cascadeRural South AfricaLocal primary care clinicsCD4 count resultsCommunity-based voluntary counselingPrimary care clinicsHIV-positive clientsPhlebotomy servicesResource-limited settingsART initiationHIV careART eligibilityCare cascadeCare clinicsHIV-positiveVoluntary counselingTreatment eligibilityCD4 resultsResult notificationResultsBetween 2010Nurse presence
2015
Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
Rodger A, Lampe F, Grulich A, Fisher M, Friedland G, Phanuphak N, Bogner, Pereira L, Rietmeijer C, Burman W, Phillips A, Group I. Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine 2015, 16: 64-76. PMID: 25711325, PMCID: PMC4341939, DOI: 10.1111/hiv.12235.Peer-Reviewed Original ResearchConceptsAntiretroviral treatmentCondomless sexHIV-1 RNA copies/Risk behaviorsRegion of recruitmentSelf-reported risk behaviorsHIV viral loadHIV-positive participantsRNA copies/Transmission risk behaviorsHIV-positive peopleSubstantial proportionRecent sexual behaviorHeterosexual menSerodifferent partnersMedian ageRisk behavior questionnaireViral loadClinical statusLifestyle factorsBlack ethnicityCopies/Trial participantsStart StudyWhite ethnicity
2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms